MEDI 0457

Drug Profile

MEDI 0457

Alternative Names: INO-3112; INO-9012/VGX-3100; MEDI-0457; VGX-3100/INO-9012

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; MedImmune; University of Pennsylvania
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Cervical cancer

Most Recent Events

  • 20 Feb 2018 MD Anderson Cancer Center in collaboration with AstraZeneca and Inovio Pharmaceuticals plans a phase II trial for Cancers associated with Human Papilloma Virus in USA , (NCT03439085)
  • 08 Jan 2018 Phase-II clinical trials in Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IM)
  • 01 Nov 2017 Inovio Pharmaceuticals completes a phase I/II trial in Head and neck cancer (associated with human papillomavirus) in USA (IM) (NCT02163057)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top